- Vutrisiran, sold
under the
brand name
Amvuttra, is a
medication used for the
treatment of the
polyneuropathy of
hereditary transthyretin-mediated (hATTR)...
- 1056/NEJMoa2107454. PMID 34215024. S2CID 235722446. "Alnylam
Announces FDA
Approval of
Amvuttra (vutrisiran), an RNAi
Therapeutic for the
Treatment of the Polyneuropathy...
- (USAN)
Amtagvi amtolmetin guacil (INN)
amustaline dihydrochloride (USAN)
amuvatinib (USAN, INN)
Amvaz Amvisc Amvuttra amylmetacresol (INN)
Amytal Amzyos...
- S2CID 232482623.
Research Cf (27
November 2023). "Drug
Trial Snapshots:
AMVUTTRA". FDA. "
Amvuttra |
European Medicines Agency". www.ema.europa.eu. 12
October 2022...
- ONPATTRO, GIVLAARI, OXLUMO, and LEQVIO. The
fifth RNAi
therapeutic medicine,
AMVUTTRA, was
approved in 2021. At Alnylam, he
forged over 25
major partnerships...
